On Thursday, Evercore ISI updated its financial outlook for Travere Therapeutics (NASDAQ:TVTX), increasing the price target to ...

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

Nivalis Therapeutics, Inc. (NASDAQ:NVLS) announced that it has dosed the first patient in a second phase II study on its lead ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.